CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,935 enrolled
Drug / intervention
Telcagepant 140 mg +2 moredrug
Likely dose
Telcagepant 140 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00483704
NCT00483704Phase 3Completed
CompareCT.gov

A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Without Aura

Merck Sharp & Dohme LLC·interventional·Posted Jun 7, 2007·Updated Oct 18, 2018

In Brief

A Phase 3 clinical trial evaluating Telcagepant 140 mg, Talcagepant 280 mg, and 1 other intervention for Migraines. Completed, enrolled 1,935 participants.

Detailed Summary

The purpose of the study is to assess the safety and efficacy of telcagepant (MK-0974) in acute treatment of multiple migraine attacks with or without aura. Primary hypotheses of this study are that telcagepant is superior to placebo, as measured by the proportion of participants who have pain freedom, pain relief, pain freedom consistency, pain relief consistency, and absence of photophobia, phonophobia, and nausea at 2 hours post-dose.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraines
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 7, 2007
Enrollment StartAug 14, 2008
Primary CompletionMar 25, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 19.1 years ago

Interventions

Telcagepant 140 mgdrug

Telcagepant 140 mg tablets

Talcagepant 280 mgdrug

Telcagepant 280 mg tablets

Placebodrug

Placebo tablets